Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Genitourinary 2

Conditions

Breast Neoplasms 133Neoplasms 114Prostatic Neoplasms 63Lung Neoplasms 47Head and Neck Neoplasms 46Colorectal Neoplasms 35Ovarian Neoplasms 33Uterine Cervical Neoplasms 28Endometrial Neoplasms 23Motor Activity 22Neoplasm Metastasis 20Multiple Myeloma 19Brain Neoplasms 19Pancreatic Neoplasms 18Rectal Neoplasms 17Lymphoma 16Fatigue 16Carcinoma, Non-Small-Cell Lung 16Pain 15Gastrointestinal Neoplasms 15Colonic Neoplasms 15Leukemia 14Depression 14Oropharyngeal Neoplasms 13Urinary Bladder Neoplasms 12Melanoma 12Hematologic Neoplasms 12Esophageal Neoplasms 12Anxiety Disorders 12Stomach Neoplasms 11

Interventions

pembrolizumab 37Gemcitabine 29Nivolumab 20Cisplatin 19atezolizumab 15avelumab 14Docetaxel 13enfortumab vedotin 10Carboplatin 10durvalumab 9Magnetic Resonance Spectroscopy 9Ipilimumab 8Paclitaxel 7Pemetrexed 6toripalimab 5cabozantinib 5Fluorodeoxyglucose F18 5sacituzumab govitecan 4cabazitaxel 4Taxes 4vinflunine 3tremelimumab 3pemigatinib 3X-Rays 3Standard of Care 3Specimen Handling 3Radiotherapy 3Mitomycin 3Immunotherapy 3Immunoglobulin G 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Transitional Cell × Surveys and Questionnaires × Clear all
NCT04566029 2025-12-10

AMI

Centre Hospitalier Universitaire de Nīmes

Completed
40 enrolled
Genitourinary

Carcinoma, Transitional Cell

NCT03106610 2018-05-24

Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy

M.D. Anderson Cancer Center

Phase 1 Terminated
1 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡